Dr. Alexander Bondoc · Clinical heterogeneity of pediatric hepatocellular carcinoma
Follow
Article1 min read·Published Apr 2020Older

Clinical heterogeneity of pediatric hepatocellular carcinoma

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · Apr 2020 · 1 min read

In brief

In brief

Retrospective study of 32 pediatric HCC patients reveals significant clinical heterogeneity, with 53% having genetic/anatomic predispositions and two distinct histologic subtypes. Surgical resection was the primary determinant of survival (66% vs 22% with medical therapy alone), with liver transplantation enabling cure in select stage 3 patients.

Written by the GCMD Library team from the article.

Alexander Bondoc

Background: Hepatocellular carcinoma (HCC) is often a chemoresistant neoplasm with a poor prognosis. Pediatric HCC may reflect unique biological and clinical heterogeneity. Procedure: An IRB-approved retrospective institutional review of patients with HCC treated between 2004 and 2015 was undertaken. Clinical, radiographic, and histologic data were collected from all patients. Results: Thirty-two patients with HCC, median age 11.5 years (range 1-20) were identified. Seventeen patients had a genetic or anatomic predisposition. Histology was conventional HCC (25) and fibrolamellar HCC (7). Evans staging was 1 (12); 2 (1); 3 (10); 4 (9). Sixteen patients underwent resection at diagnosis and five patients after neoadjuvant chemotherapy. Surgical procedures included liver transplantation (LT, 11), hemihepatectomy (9), and segmentectomy (1). Eighteen patients had medical therapy (13 neoadjuvant, 5 adjuvant). Most common initial medical therapy included sorafenib alone (7) and cisplatin/doxorubicin-based therapy (8). Overall, 14 (43.8%) patients survived with a median follow-up of 58.8 months (range 26.5-157.6). Cause of death was most often linked to lack of primary tumor surgery (11). Of the survivors, Evans stage was 1 (11), 2 (1), and 3 (2, both treated with LT). Four of 18 patients (22%) who received medical therapy, 8 of 17 patients with a predisposition (47%), and 14 of 21 patients (66%) who underwent surgery remain alive. Conclusions: Genetic and anatomic predisposing condit

Statements in this article

  1. Hepatocellular carcinoma is often a chemoresistant neoplasm with a poor prognosis.

    EstablishedBackground
  2. The median age of pediatric hepatocellular carcinoma patients in this series was 11.5 years with a range of 1-20 years.

    ResearchResults
  3. Seventeen of 32 patients (53%) had a genetic or anatomic predisposition to hepatocellular carcinoma.

    ResearchResults
  4. Histology was conventional HCC in 25 patients and fibrolamellar HCC in 7 patients.

    ResearchResults
  5. Evans staging distribution was stage 1 in 12 patients, stage 2 in 1 patient, stage 3 in 10 patients, and stage 4 in 9 patients.

    ResearchResults
  6. Sixteen patients underwent resection at diagnosis and five patients underwent resection after neoadjuvant chemotherapy.

    ResearchResults
  7. Surgical procedures included liver transplantation in 11 patients, hemihepatectomy in 9 patients, and segmentectomy in 1 patient.

    ResearchResults
  8. Eighteen patients received medical therapy, with 13 receiving neoadjuvant therapy and 5 receiving adjuvant therapy.

    ResearchResults
  9. The most common initial medical therapies were sorafenib alone in 7 patients and cisplatin/doxorubicin-based therapy in 8 patients.

    ResearchResults
  10. Overall survival was 43.8% (14 of 32 patients) with a median follow-up of 58.8 months (range 26.5-157.6 months).

    ResearchResults
  11. Cause of death was most often linked to lack of primary tumor surgery in 11 patients.

    ResearchResults
  12. Among survivors, Evans stage distribution was stage 1 in 11 patients, stage 2 in 1 patient, and stage 3 in 2 patients (both treated with liver transplantation).

    ResearchResults
  13. Four of 18 patients (22%) who received medical therapy survived.

    ResearchResults
  14. Eight of 17 patients (47%) with a genetic or anatomic predisposition survived.

    ResearchResults
  15. Fourteen of 21 patients (66%) who underwent surgery survived.

    ResearchResults

Read it at the source ↗

Intelligent Search· scoped to this article · not medical adviceSearch the whole library →
GCMD Library — educational content from recorded physician discussions, not medical advice.